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North Carolina, USAA B S T R A C TObjectives: The NADiA ProsVue is a prognostic system that measures
prostate-speciﬁc antigen slope to identify men at lower risk of clinical
recurrence of prostate cancer after radical prostatectomy. We developed a
decision-modeling framework to evaluate its cost-effectiveness to guide the
use of adjuvant radiotherapy (ART). Methods: We populated the model
using patient-level data and external sources. Patients were classiﬁed as
intermediate risk or high risk on the basis of Cancer of the Prostate Risk
Assessment-Postsurgical (CAPRA-S) nomogram and then stratiﬁed by the
ProsVue slope (r2 pg/mL/mo; 42 pg/mL/mo) and receipt of ART. In
sensitivity analyses, we varied the effect of the ProsVue slope on the use
of ART and other model parameters. Results: The cost-effectiveness of the
ProsVue-guided strategy varied widely because of small differences in
quality-adjusted life-years (QALYs) at 10 years. In the intermediate-risk
group, when the use of ART decreased from 20% (standard care) to 7.5%
among patients with a ProsVue slope value of 2 pg/mL/mo or less, theee front matter Copyright & 2014, International S
r Inc.
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ndence to: Shelby D. Reed, Duke Clinical Researchincremental cost-effectiveness ratio was $25,160/QALY. In the high-risk
group, the use of ART would have to decrease from 40% (standard care) to
11.5% among those with a ProsVue slope value of 2 pg/mL/mo or less to
obtain a ratio of $50,000/QALY. The cost-effectiveness ratios were sensitive
to varying beneﬁts of salvage therapy, quality of life, and costs of ART and
ProsVue testing. Conclusions: The effect of the ProsVue system on costs
will be dependent on the extent to which ART decreases among men
identiﬁed as having a low risk of recurrence. Its effect on QALYswill remain
conditional on uncertain clinical and quality-of-life beneﬁts associated with
ART.
Keywords: cost-beneﬁt analysis, prostate-speciﬁc antigen, prostate
cancer.
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Outcomes Research (ISPOR). Published by Elsevier Inc.Introduction
In contemporary practice, approximately 1 in 6 men diagnosed with
prostate cancer undergoes radical prostatectomy [1]. Among patients
with higher-risk pathological characteristics, recurrence rates range
from 40% to 60% [2,3]. In recent randomized controlled trials,
adjuvant radiotherapy (ART) after radical prostatectomy in high-
risk patients signiﬁcantly improved biochemical recurrence–free
survival [4–7].
On the basis of these ﬁndings, practice guidelines suggest that
physicians offer ART to patients with high-risk pathologic ﬁndings
while informing them that the beneﬁts of ART on metastatic disease
and overall survival have not been demonstrated clearly in clinical
trials [8]. Nevertheless, most patients do not experience clinical
recurrence with or without ART, and direct medical costs, patient
time costs, and adverse effects associated with adjuvant or salvage
therapy are signiﬁcant [9–11]. Better prognostic models of the risk ofclinical recurrence can help urologists personalize adjuvant therapy
after prostatectomy.
NADiA ProsVue is a prognostic system that uses a highly
sensitive immuno–polymerase chain reaction assay to measure
extremely low concentrations (i.e., picograms) of prostate-speciﬁc
antigen (PSA) across three blood samples taken on separate
occasions from 1.5 to 20.0 months after prostatectomy. In an
analysis of 304 patients from four clinical sites, the ProsVue PSA
slope was a statistically signiﬁcant predictor of clinical progression-
free survival within Cancer of the Prostate Risk Assessment-
Postsurgical (CAPRA-S) risk groups deﬁned by six postsurgical risk
factors: preoperative PSA level, surgical margins, seminal vesicle
invasion, pathologic Gleason score, extracapsular extension, and
lymph node invasion [12–14]. As a prognostic marker, the ProsVue
slope is dichotomized to represent patients at reduced risk of
clinical recurrence within 8 years (PSAr 2 pg/mL/mo) and patients
not at reduced risk for clinical recurrence (PSA 4 2 pg/mL/mo).ociety for Pharmacoeconomics and Outcomes Research (ISPOR).
Institute, PO Box 17969, Durham, NC 27715.
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medical technology can identify issues that are most inﬂuential
in determining its value and areas to focus additional data
collection [15,16]. We developed a decision-analytic model to
establish a framework to evaluate the potential cost-
effectiveness of ProsVue as an adjunctive prognostic marker to
CAPRA-S risk stratiﬁcation in comparison with the use of post-
operative characteristics alone as characterized by the CAPRA-S
risk group (i.e., standard care). The evaluation is limited to
patients with intermediate-risk and high-risk CAPRA-S scores
consistent with treatment guidelines [8]. We report ﬁndings
across a range of scenarios, including those in which the effect
of the ProsVue slope is limited to decreasing the use of ART when
the ProsVue slope value is 2 pg/mL/mo or less (i.e., the threshold
in the US Food and Drug Administration [FDA] label indication to
report that a patient is “at reduced risk” of clinical recurrence)
and those in which ART increases when the ProsVue slope value
is more than 2 pg/mL/mo.Methods
Model Structure
We developed a probabilistic decision-analytic model to estimate
costs and quality-adjusted survival in a target population con-
sisting of men with prostate cancer who recently underwent
radical prostatectomy. We used a decision tree to group patients
according to intermediate-risk and high-risk CAPRA-S scores as
deﬁned by Cooperberg et al. [13], which incorporates character-
istics such as surgical margin status, pathologic Gleason score,
and lymph node invasion [13]. We then stratiﬁed patients by
ProsVue slope and receipt of ART (Fig. 1). After stratifying patients
into risk groups, we developed a state transition model that uses
monthly cycles to generate costs and outcomes associated with
treatment and disease progression. After prostatectomy, patients
can develop biochemical recurrence (based on standard PSA
testing) at rates that vary across the four risk groups and receipt
of ART. Patients who develop biochemical recurrence can prog-
ress to distant disease and subsequently die of prostate cancer.
Patients in any health state can die of competing causes. To
capture negative consequences associated with ART and salvage
radiotherapy, we integrated tunnel states representing the time
with adverse effects of radiotherapy.
Model Inputs
Table 1 lists the values for the model parameters representing a
US private payer scenario. The proportions of patients stratiﬁed
by CAPRA-S risk group and ProsVue slope are based on the cohort
of 304 patients included in studies to support 510(k) registration
of ProsVue with the FDA [14]. We used patient-level data from
this cohort to generate Kaplan-Meier estimates of biochemical
recurrence in the absence of ART for each of the four risk groups.
As shown in Figure 2, the hazard ratios appear constant in the
groups with ProsVue slope values of 2 pg/mL/mo or less, but they
varied by time in groups with ProsVue slope values of more than
2 pg/mL/mo. To reﬂect this ﬁnding, we applied separate transi-
tion probabilities for the ﬁrst 5 years and after 5 years for the
groups with ProsVue slope values of more than 2 pg/mL/mo.
In the main analyses, effects of ART on the development of
biochemical recurrence and the use of salvage therapy were
based on 11-year randomized trial results from the European
Organisation for Research and Treatment of Cancer [7]. We
estimated transition probabilities representing the development
of distant disease and death following distant disease in the
absence of salvage therapy [17], and we modeled beneﬁts fromsalvage therapy as reported by Trock et al. [18]. Salvage therapy
(i.e., treatment after biochemical recurrence) for patients who
had received ART consisted of androgen deprivation therapy
(ADT). For patients who had not received ART, salvage therapy
consisted of radiotherapy. We assumed that beneﬁts of salvage
therapy applied to patients who had or had not received ART on
the basis of a separate external validation exercise, as recom-
mended for model-based studies [19], in which we found that this
assumption provided more accurate approximation of distant
disease and overall survival at 10 years reported in clinical trials
(see Appendix in Supplemental Materials found at http://dx.doi.
org/10.1016/j.jval.2014.04.010) [4,5,7]. We modeled age-dependent
rates of nonprostate cancer death using data from the National
Center for Health Statistics [20].
Use of ART and Impact of ProsVue Slope
With standard care, we assumed that 20% and 40% of the patients
in the intermediate-risk and high-risk CAPRA-S groups would
receive ART, respectively. These rates are slightly higher than
those reported by Williams et al. [21] for Medicare beneﬁciaries
(14% and 36% in intermediate and high D’Amico risk groups) to
represent higher use of ART in younger, privately insured
populations [22].
The extent to which ProsVue information changes practice
patterns is not yet known. Therefore, in the FDA label scenarios
when the ProsVue slope value was 2 pg/mL/mo or less, we
decreased the use of ART by 5 to 15 percentage points in the
intermediate-risk CAPRA-S group and by 5 to 25 percentage
points in the high-risk CAPRA-S group. To represent the possi-
bility that ART could also increase for patients with higher
ProsVue slope values, we increased the use of ART by up to 10
and 20 percentage points in the intermediate- and high-risk
CAPRA-S groups, respectively.
Unit Costs and Utility Weights
Details regarding unit costs are provided in the Appendix in
Supplemental Materials found at http://dx.doi.org/10.1016/j.jval.
2014.04.010. To represent the private payer perspective, we
increased costs for ART derived from 2013 Medicare reimbursement
rates [23] by a factor of 1.64, which represents the median ratio of
payments by private payers relative to Medicare reimbursement
across seven medical procedures [24]. For costing purposes, we
assumed that 31% of the patients who received adjuvant or salvage
radiotherapy also received concomitant hormonal therapy [25]. We
set the cost of ProsVue testing at $3000.
We applied utility weights published by Stewart et al. [26] to
time spent in various health states in the model. In the main
analyses, we applied a utility decrement of 0.11 for a 1-year
period after radiotherapy derived from the difference in utility
weights reported for symptoms occurring with radiotherapy
(0.73) relative to a low risk of recurrence (0.84) [25,27].
Discounting and Time Horizon
We discounted costs and quality-adjusted survival at 3% per year
[28]. The time horizon was 10 years, and we assumed that patients
were aged 60 years when they underwent prostatectomy.
Sensitivity Analysis
To perform probabilistic sensitivity analysis, we assigned stat-
istical distributions to the model inputs to represent uncertainty
associated with point estimates [29]. We used beta distributions
to model dichotomous variables and disutility weights and
lognormal distributions to model hazard ratios for treatment
beneﬁts. Proportions of patients receiving ART and salvage
Fig. 1 – Schematic of the decision tree and state transition model. CAPRA-S, Cancer of the Prostate Risk Assessment-
Postsurgical; RP, radical prostatectomy.
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Table 1 – Values of parameters represented in the decision model.
Parameter Standard care ProsVue slope Source
42 pg/mL/mo r2 pg/mL/mo
Patients in each risk group
CAPRA-S intermediate risk (%) 63.5 21.3 78.7 Patient-level data from 510(k) study (n ¼ 94)
CAPRA-S high risk (%) 36.5 59.3 40.7 Patient-level data from 510(k) study (n ¼ 54)
Use of ART
CAPRA-S intermediate risk (%) 20 20–30* 5–15 Expert opinion with benchmark based on
the use of ART reported by Williams
et al. [21] for Medicare beneﬁciaries in
D’Amico intermediate-risk group (14%)
increased to account for higher use in
younger, privately insured patients.
CAPRA-S high risk (%) 40 40–60* 15–35 Expert opinion with benchmark based on
the use of ART reported by Williams
et al. [21] among Medicare beneﬁciaries
in D’Amico high-risk group (36%)
increased to account for higher use in
younger, privately insured patients.
Annual transition probability in
Markov model
Development of BCR See Figure 3 Patient-level data from 510(k) study
CAPRA-S intermediate risk
ProsVue r2 pg/mL/mo 0.015
ProsVue 42 pg/mL/mo, 0–5 y 0.316
ProsVue42 pg/mL/mo, 5–10 y 0.37
CAPRA-S high risk
ProsVue r2 pg/mL/mo 0.040
ProsVue 42 pg/mL/mo, 0–5 y 0.749
ProsVue42 pg/mL/mo, 5–10 y o0.001†
BCR to distant disease without
salvage therapy
0.088 Pound et al. [17], retrospective natural
history study of 1997 men with BCR
postprostatectomy and did not receive
salvage therapy with median follow-up
of 5.3 y
Distant disease to death 0.188 Pound et al. [17], see above
Beneﬁts of ART and salvage
therapy
Beneﬁt of ART on BCR, HR (95%
CI)
0.49 (0.41–0.59) Bolla et al. [7], RCT of 1005 men followed for
a median of 10.6 y
Concomitant ADT with ART or
salvage radiation therapy (%)
31 Goenka et al. [25]
Salvage ADT on BCR among
patients who received ART
(%)
82 Bolla et al. [7], see above
Salvage radiotherapy on BCR
among patients who did not
receive ART (%)
82 Bolla et al. [7], see above
Beneﬁt of salvage radiotherapy
on distant disease for
patients who did not receive
ART, HR (95% CI)
0.32 (0.19–0.54) Trock et al. [18], retrospective analysis of
635 men with a median follow-up of 6 y
Beneﬁt of salvage ADT on
distant disease for patients
who received ART, HR (95%
CI)
0.32 (0.19–0.54) Trock et al. [18], see above
Cost (US $)
ProsVue 3,000 Assumption
Adjuvant or salvage
radiotherapy
30,200 2013 Medicare reimbursement [37];
increased by 64% to estimate payments
by private payers [23]‡; see Appendix for
details
Annual cost of monitoring for
recurrence‡
Year 1 1,028
Year 2 514
Year 3 and beyond 257
Annual cost after BCR 1,601
Androgen deprivation therapy 6,192
Metastatic disease 50,000 Assumption
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Table 1 – continued.
Parameter Standard care ProsVue slope Source
42 pg/mL/mo r2 pg/mL/mo
Utility (SE)
CAPRA-S intermediate after
prostatectomy
0.81 (0.19) Stewart et al. [26], prospective preference
elicitation study of men with (n ¼ 84) and
without (n ¼ 78) prostate cancerCAPRA-S high after
prostatectomy
0.71 (0.29)
BCR 0.67 (0.33)
Metastatic disease 0.25 (0.75)
Additional disutility associated
with ART (1 y)
–0.11 Derived from Stewart et al. [26]; duration
from Moinpour et al. [27], subset analysis
of 217 men enrolled in RCT with 5 y of
follow-up
Discount rate (%) US Public Health Service Panel [26]
Costs 3
Life-years/quality-adjusted life-
years
3
ADT, androgen deprivation therapy; ART, adjuvant radiotherapy; BCR, biochemical recurrence; CAPRA-S, Cancer of the Prostate Risk
Assessment-Postsurgical; CI, conﬁdence interval; FDA, Food and Drug Administration; HR, hazard ratio; RCT, randomized controlled trial;
SE, standard error.
* A scenario consistent with the FDA label includes 20% at intermediate risk and 40% at high risk.
† This transition probability is unnecessary given that all patients will have developed BCR within 5 y.
‡ See Appendix for details related to cost estimates.
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multiple one-way sensitivity analyses.Results
Intermediate-Risk CAPRA-S
In the FDA label scenarios, in which the use of ART decreased when
the ProsVue slope value was 2 pg/mL/mo or less, the incremental
cost-effectiveness ratios (ICERs) ranged from more than $600,000/
QALY when the use of ART decreased from 20% to 15% to being
economically dominant (ie, cost saving and QALY increasing) when
the use of ART decreased from 20% to 5% (Table 2). When the use of
ART was reduced to 8.24% in the ProsVue-guided strategy, the ICER
was approximately $50,000/QALY. When the use of ART dropped
below 6.5% with the lower ProsVue slope, the ProsVue-guided
strategy was cost saving.
In scenarios in which the use of ART increased when the ProsVue
slope value wasmore than 2 pg/mL/mo, mean costs at 10 years wereFig. 2 – Biochemical recurrence over time by risk group. CAPRhigher by $68 per 5 percentage-point increase in ART when holding
constant the effect of ART in the group with lower ProsVue slope
values. This cost increase coincided with a greater gain in QALYs
(0.004), which improved the cost-effectiveness of the ProsVue-guided
strategy. For example, at 10% use of ART among patients with
ProsVue slope values of 2 pg/mL/mo or less, the ICER dropped to
$81,729/QALY when the use of ART increased from 20% to 25%
among patients with ProsVue slope values greater than 2pg/mL/mo.High-Risk CAPRA-S
Among patients in the high-risk CAPRA-S group in which we
assumed that 40% of the patients received ART with standard
care, estimated mean costs and QALYs at 10 years were $39,346
and 5.131 (discounted). For each 5 percentage-point decrease in
the use of ART with ProsVue slope values of 2 pg/mL/mo or less,
mean costs decreased by $480 while QALYs increased approx-
imately 0.01. For an ICER of $50,000/QALY, ART would have to
decrease to 11.5% among patients with ProsVue slope values of
2 pg/mL/mo or less. Conversely, for each 5 percentage-pointA-S, Cancer of the Prostate Risk Assessment-Postsurgical.
Table 2 – Results of base-case analyses with varying effects of ProsVue slope on the use of ART.
Use of ART (%) ProsVue Standard care ProsVue –
standard care
ICER
($/QALY)
Standard
care
ProsVue
slope 42
ProsVue
slope r2
Cost
($)
QALYs Cost
($)
QALYs Cost
($)
QALYs
CAPRA-S intermediate risk
20 20 (FDA label) 15.0 21,030 6.183 19,154 6.180 1,876 0.003 620,152
10.0 19,906 6.186 752 0.006 124,326
7.5 19,344 6.188 190 0.008 25,160*
5.0 18,782 6.189 –372 0.009 Dominant
20 25 20.0 22,222 6.184 19,154 6.180 3,068 0.004 769,666
15.0 21,098 6.187 1,944 0.007 277,285
10.0 19,974 6.190 820 0.010 81,729
7.5 19,412 6.192 258 0.012 22,369
5.0 18,859 6.193 –304 0.013 Dominant
20 30 20.0 22,290 6.188 19,154 6.180 3,136 0.008 393,369
15.0 21,166 6.191 2,012 0.011 182,968
10.0 20,042 6.194 888 0.014 63,349
7.5 19,480 6.196 326 0.016 21,010
5.0 18,918 6.197 –236 0.017 Dominant
CAPRA-S high risk
40 40 (FDA label) 35.0 41,867 5.132 39,346 5.131 2,520 0.001 2,706,711
30.0 41,387 5.133 2,040 0.002 1,095,730
25.0 40,907 5.133 1,561 0.003 558,737
20.0 40,427 5.134 1,081 0.004 290,240*
15.0 39,948 5.135 601 0.005 129,142
40 45 40.0 42,497 5.133 39,346 5.131 3,150 0.002 1,260,708
35.0 42,017 5.134 2,671 0.003 778,599
30.0 41,537 5.135 2,191 0.004 502,355
25.0 41,058 5.136 1,711 0.005 323,317
20.0 40,578 5.137 1,231 0.006 197,853
15.0 40,098 5.138 752 0.007 105,046
40 50 40.0 42,647 5.136 39,346 5.131 3,301 0.005 660,430
35.0 42,167 5.137 2,821 0.006 475,791
30.0 41,688 5.138 2,341 0.007 341,275
25.0 41,208 5.138 1,861 0.008 238,911
20.0 40,728 5.139 1,382 0.009 158,402
15.0 40,248 5.140 902 0.010 93,425
40 55 40.0 42,797 5.138 39,346 5.131 3,451 0.007 430,338
35.0 42,318 5.139 2,971 0.008 454,026
30.0 41,383 5.140 2,491 0.009 266,213
25.0 41,358 5.141 2,012 0.010 195,500
20.0 40,878 5.142 1,532 0.011 136,523
15.0 40,399 5.143 1,052 0.012 86,583
40 60 40.0 42,948 5.141 39,346 5.131 3,601 0.010 360,291
35.0 42,468 5.142 3,121 0.011 285,681
30.0 41,988 5.143 2,642 0.012 222,789
25.0 41508 5.143 2,162 0.013 169,054
20.0 41,029 5.144 1,682 0.014 122,613
15.0 40,549 5.145 1,202 0.015 82,075
ART, adjuvant radiotherapy; CAPRA-S, Cancer of the Prostate Risk Assessment-Postsurgical; FDA, US Food and Drug Administration; ICER,
incremental cost-effectiveness ratio; QALY, quality-adjusted life-year.
* Scenarios used in sensitivity analyses for intermediate-risk and high-risk CAPRA-S groups.
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values of more than 2 pg/mL/mo, mean costs increased by $150
and QALYs increased by 0.0025.
There were greater cost savings (–$480 per 5 percentage points)
with reductions in ART among patients with ProsVue slope values
of 2 pg/mL/mo or less than cost increases ($150) with commensu-
rate increases in ART among patients with ProsVue slope values of
more than 2 pg/mL/mo. This result occurred because there was
greater opportunity for cost avoidance for patients in the lower-risk group (based on ProsVue slope) than in the higher-risk group
because these patients were less likely to experience disease
progression and associated costs when forgoing ART.
Sensitivity Analyses
Figure 3 shows the results from two sets of 1000 Monte Carlo
simulations when we varied the parameter values in probabilistic
sensitivity analyses for the scenarios consistent with the labeling
Fig. 3 – Scatter plots of two sets of 1000 model simulations representing differences in costs and QALYs with ProsVue-guided
therapy versus standard care in the CAPRA-S intermediate-risk and high-risk groups in select scenarios consistent with
ProsVue labeling. Note. Results for the intermediate-risk CAPRA-S group represent the scenario in which ART is reduced from
20% to 7.5% among patients with ProsVue slope values of 2 pg/mL/mo or less and the use of ART remains at 20% in men with
ProsVue slope values of more than 2 pg/mL/mo. Results for the high-risk CAPRA-S group represent the scenario in which ART
is reduced from 40% to 20% among patients with ProsVue slope values of 2 pg/mL/mo or less and remains at 40% in patients
with ProsVue slope values of more than 2 pg/mL/mo. CAPRA-S, Cancer of the Prostate Risk Assessment-Postsurgical; QALY,
quality-adjusted life-year.
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CAPRA-S group wherein the use of ART is reduced from 20% to
7.5% among patients with ProsVue slope values of 2 pg/mL/mo or
less and the use of ART remains at 20% with ProsVue slope values
of more than 2 pg/mL/mo. The second set of simulations
represents the high-risk CAPRA-S group wherein the use of ART
is reduced from 40% to 20% among patients with ProsVue slope
values of 2 pg/mL/mo or less. In the intermediate-risk CAPRA-S
group, 83.6% and 98.3% of the simulations were consistent with
ICERs of less than $50,000/QALY and $100,000/QALY, respectively.
For the high-risk CAPRA-S group, 7.4% of the simulations were
consistent with ICERs of less than $100,000/QALY.
The results from one-way sensitivity analyses are reported in
Table 3. The ICERs were highly sensitive to changes in assump-
tions pertaining to quality of life across time and the cost of ART
and the ProsVue system. Increasing the duration over which
patients experience toxicities associated with radiotherapy
resulted in more favorable ICERs, as did applying small increases
in utility weights (i.e., 0.01 or 0.05) across 3 years to represent
reduced anxiety associated with having ProsVue slope values of 2
pg/mL/mo or less. At lower costs for ART, the cost-effectiveness
of the ProsVue-guided strategy was less attractive. If the cost of
ART surpasses $32,336, however, the PSA slope-guided strategy
becomes cost saving for the intermediate-risk CAPRA-S group. At
a $50,000/QALY threshold for conferring cost-effectiveness, the
ProsVue system could cost up to $3188 for the intermediate-risk
CAPRA-S group and $2105 for the high-risk CAPRA-S group.Discussion
Our decision model provides an explicit framework to illuminate
which factors most affect the potential cost-effectiveness ofProsVue-guided therapy for patients with high-risk character-
istics after radical prostatectomy for prostate cancer. We found
that its potential cost-effectiveness is more attractive among
patients in the intermediate-risk CAPRA-S group than among
patients classiﬁed as high risk and when testing is directed
toward patients who have greater anxiety about forgoing ART
and patients who are more likely to experience toxicities
from ART.
These ﬁndings stem from the relatively small incremental
beneﬁt of ART on survival embedded in the model (i.e., about 1
percentage point at 10 years). Although a strategy that aims to
reduce the use of ART could lead to shorter overall survival, there
may be gains in quality-adjusted survival due to a reduction in
toxicities associated with ART. This gain, however, would be
counterbalanced by the expectation that these patients could
spend more time with biochemical recurrence across 10 years.
However, the numerator of the cost-effectiveness ratio (i.e.,
difference in costs) demonstrated larger changes across the
scenarios evaluated. In the main analysis for the intermediate-
risk CAPRA-S group, when ART declined from 20% (standard care)
to 7.5% when the ProsVue slope value is 2 pg/mL/mo or less,
nearly 94% of the $3000 cost of the ProsVue system was offset
within 10 years. Cost savings in the high-risk CAPRA-S group
were smaller, because only 4 in 10 men tested were expected to
have a lower ProsVue slope value.
Early economic modeling can identify model parameters that
have the greatest effect on the cost-effectiveness of ProsVue-
guided therapy. First, although the cost of a ProsVue slope result
was important, it would be a known value to an individual
stakeholder making a coverage decision. Second, the extent to
which ART is recommended with standard care within CAPRA-S
risk groups has not been documented in the literature. Yet, it is
an important factor in determining the cost-effectiveness of
Table 3 – Sensitivity analyses.
Description Intermediate risk* High risk†
Difference
in cost ($)
Difference
in QALYs
$/QALY Difference
in cost ($)
Difference
in QALYs
$/QALY
Base-case analysis 190 0.008 25,160 1,081 0.004 290,240
Age
Decrease to 55 y 198 0.007 26,583 1,095 0.004 307,990
Increase to 65 y 179 0.008 23,064 1,059 0.004 265,978
Beneﬁt of ART
Beneﬁt observed in SWOG8794 (HR,
0.71)
145 0.010 14,475 1,004 0.006 169,284
No beneﬁt of salvage radiotherapy 273 0.004 64,762 1,213 –0.003 Dominated
No beneﬁt of salvage ADT 148 0.009 16,008 992 0.007 134,271
No beneﬁt of salvage radiotherapy
and ADT
232 0.006 39,038 1,124 o0.001 2,599,207
Utility weights
Change mean duration of utility
decrement with ART (–0.11) from
1 y to 2 y
–‡ 0.019 10,012 –‡ 0.012 90,105
Change mean duration of utility
decrement with ART (–0.11) from
1 y to 3 mo
–‡ –0.002 Dominated –‡ –0.003 Dominated
Set utility weight for biochemical
recurrence equal to utility weight
without biochemical recurrence
(0.81 and 0.71 for CAPRA
intermediate- and high-risk groups,
respectively)
–‡ 0.011 17,516 –‡ 0.006 193,997
Change utility decrement with ART
from –0.11 to –0.2 (1 y)
–‡ 0.018 10,514 –‡ 0.011 97,367
Apply utility beneﬁt of 0.01 for 3 y for
men with known PSA slope r2 pg/
mL/mo
–‡ 0.029 6,506 –‡ 0.015 74,091
Apply utility beneﬁt of 0.05 for 3 y for
men with known PSA slope r2 pg/
mL/mo
–‡ 0.116 1,641 –‡ 0.058 18,621
Unit costs ($)
Cost of ProsVue testing
1000 –1,810 –‡ Dominant –919 –‡ Dominant
2000 –810 –‡ Dominant 81 –‡ 21,743
3000 (value in main analysis) 190 –‡ 25,160 1,081 –‡ 290,240
4000 1,190 –‡ 157,381 2,081 –‡ 558,737
Quadruple cost of distant disease to
200,000
327 –‡ 43,192 1,291 –‡ 346,594
Reduce cost of ART to 18,415
(Medicare 2013 reimbursement)
1,238 –‡ 163,743 1,824 –‡ 489,660
Increase cost of ART to 50,000 –1,571 –‡ Dominant –167 –‡ Dominant
Double cost of ADT to 12,387 –9 –‡ Dominant 936 –‡ 251,316
Time horizon
15 y 325 0.001 245,444 1,307 –0.004 Dominated
30 y 517 0.015 Dominated 1,080 –0.026 Dominated
ADT, androgen deprivation therapy; ART, adjuvant radiotherapy; CAPRA-S, Cancer of the Prostate Risk Assessment-Postsurgical; HR, hazard
ratio; PSA, prostate-speciﬁc antigen; QALYs, quality-adjusted life-years.
* Use of ART includes 20% with standard care, 20% with ProsVue slope 42 pg/mL/mo, and 7.5% with ProsVue slope r2 pg/mL/mo.
† Use of ART includes 40% with standard care, 40% with ProsVue slope 42 pg/mL/mo, and 20% with ProsVue slope r2 pg/mL/mo.
‡ Same estimate as in the base-case analysis. “Dominated” refers to a scenario in which PSA-guided therapy is expected to be more costly and
produce fewer QALYs than standard care. “Dominant” refers to a scenario in which PSA-guided therapy is expected to be less costly and
produce more QALYs.
V A L U E I N H E A L T H 1 7 ( 2 0 1 4 ) 5 4 5 – 5 5 4552ProsVue-guided therapy. Although an analysis of a large database
could be performed to obtain precise estimates of the use of ART
by CAPRA-S risk, practice patterns vary widely across geographicareas and physician specialties [30–32]. Thus, for an individual
decision maker, information on local practice patterns might be
more important in determining the cost-effectiveness of
V A L U E I N H E A L T H 1 7 ( 2 0 1 4 ) 5 4 5 – 5 5 4 553ProsVue-guided management. Third, consistent with previous
studies [33,34], the utility weights applied to ART-associated
toxicities and to reduced anxiety with a lower-risk ProsVue slope
value were highly inﬂuential. Future studies could elicit patient
preferences to determine the value of personalized care because
of the inherent variability in anxiety across individuals facing
similar risks [35].
Ultimately, the clinical utility and cost-effectiveness of
ProsVue-guided therapy will depend on how testing is used in
practice. The lack of this information frequently represents a
signiﬁcant challenge to making informed reimbursement deci-
sions [16,36]. To address this question, the manufacturer of
ProsVue is conducting an ongoing cohort study to document
the anticipated use of ART on enrollment and the actual use of
ART after the receipt of ProsVue slope information. By prospec-
tively establishing the model to evaluate the cost-effectiveness of
ProsVue-guided therapy, future analyses that incorporate the
documented impact of ProsVue information on the use of ART
should be considered more credible.
Our model has some limitations. We did not include additional
costs associated with obtaining and shipping blood samples for
ProsVue testing. We assumed that these blood draws would be
performed during the quarterly ofﬁce visits modeled with both
strategies during the ﬁrst year after prostatectomy. Also, the time
horizon for the main analyses was limited to 10 years. Longer time
horizons may be relevant for younger patients considering ART. As
shown in the sensitivity analyses, longer time horizons adversely
affected the cost-effectiveness of the ProsVue system. This
occurred because many patients in higher-risk groups eventually
developed distant disease despite a reduction in the rate of disease
progression with adjuvant or salvage therapy.Conclusions
We developed a modeling framework to assess the cost-
effectiveness of the ProsVue system to guide the use of ART in
men at intermediate or high risk for recurrence of prostate
cancer. We found the effect of the ProsVue system on quality-
adjusted life expectancy difﬁcult to model given uncertainties
about the relative risks and beneﬁts associated with ART based
on recent large-scale clinical trials [4–7]. Nevertheless, greater
QALY gains are expected if the ProsVue system is used preferen-
tially in patients who are more likely to experience ART-
associated toxicities or whose anxiety may be reduced when a
lower ProsVue slope is detected. Other signiﬁcant drivers of the
ProsVue system’s cost-effectiveness included the effect of the
system on the use of ART among men with lower and higher
ProsVue slope values and the cost of testing. We also found that
ProsVue slope-guided therapy is expected to be more cost-
effective for private payers who pay more for ART and ADT than
does Medicare. An ongoing study designed to document the
extent to which ProsVue slope affects the use of ART will provide
critical information on its potential to reduce health care costs.
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